查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1997391

基因組學人工智慧市場：2026-2032年全球市場預測（按人工智慧技術、服務、序列類型、應用和最終用戶分類）

Artificial Intelligence in Genomics Market by AI Technique, Service, Sequencing Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，基因組學領域的人工智慧市場價值將達到 5.2332 億美元，到 2026 年將成長到 5.5677 億美元，到 2032 年將達到 8.5443 億美元，複合年成長率為 7.25%。

主要市場統計數據
基準年 2025 5.2332億美元
預計年份：2026年 5.5677億美元
預測年份 2032 8.5443億美元
複合年成長率 (%) 7.25%

先進的計算模型、高通量定序和數據工程的融合如何重新定義基因組學中的發現、診斷和治療決策。

人工智慧正透過將演算法的嚴謹性與生物學洞見結合，迅速變革基因組學，使以往無法實現的發現成為可能。模型架構的進步、註釋資料集的廣泛應用以及雲端原生運算生態系統的蓬勃發展，都促進了基因組訊號解讀的快速與精準。計算方法與高通量定序的融合，正在為理解遺傳變異、識別治療標靶以及將分子特徵轉化為臨床可操作的決策提供新的途徑。

一種新的演算法架構、從定序到分析的整合工作流程以及聯邦協作模型，在優先考慮合規性和檢驗的同時，加速了實用化。

基因組學領域正經歷著變革性的轉變，這主要得益於模型處理能力的提升、多模態資料集的日益豐富以及端到端運算流程的日趨成熟。深度學習架構，包括卷積神經網路和循環神經網路，已被廣泛應用於需要空間模式識別和時間序列解釋的任務；而自編碼器則有助於降維和潛在表徵學習，從而揭示隱藏的生物學關係。機器學習範式，例如監督學習和無監督學習，仍然是分類和叢集任務的基礎；強化學習也開始應用於高通量環境下的實驗設計和資源分配。應用於生物醫學文獻和臨床記錄的自然語言處理技術正在改善資訊搜尋並加速假設生成。

美國累積關稅措施對基因組學領域的供應鏈、籌資策略、合作研究實踐和國內創新重點的定性影響。

2025年美國關稅政策的發展為基因組學領域的供應鏈、採購決策和研究合作帶來了一系列複雜的定性壓力。這些壓力累積，導致跨境採購的敏感度顯著增強，促使各機構重新審視供應商選擇標準，並評估試劑、儀器和計算資源供應管道的韌性。實際上，這正在加速許多相關人員尋求供應商多元化，並探索關鍵耗材和儀器的本土化生產和區域製造夥伴關係。

基於細分的洞察，了解應用需求、演算法方法、服務模型、定序方法和最終用戶優先順序如何決定基因組人工智慧的採用路徑。

從精細的細分觀點，基因組人工智慧在臨床、農業和商業應用等不同領域中最具實際價值的體現方式。在應用領域，農業和動物基因組學正受益於演算法性狀選擇和基因組選擇技術，這些技術加速了作物改良和牲畜育種，使育種者能夠更有效地優先考慮產量、適應性和抗病性。診斷領域涵蓋臨床診斷實驗室和調查診斷團隊。人工智慧透過改進變異解讀和縮短結果獲取時間來補充高通量檢測，而調查診斷則利用模式發現來產生用於後續檢驗的假設。在藥物發現領域，計算方法擴展到先導化合物識別、標靶檢驗和臨床前試驗，人工智慧模型有助於增強虛擬篩檢、預測脫靶效應和最佳化實驗優先順序。精準醫療整合了伴隨診斷、個人化治療和藥物基因體學，基於結合基因組和臨床數據識別出的預測性生物標記來最佳化治療方案。

區域市場動態影響美洲、歐洲、中東和非洲以及亞太地區的基因組人工智慧的商業化、監管和合作研究。

地理趨勢正顯著影響全球基因組學生態系統中的投資模式、法規環境和合作研究。在美洲，產業界、學術界和臨床系統之間持續保持緊密的合作，成熟的創業投資網路為轉化研究提供支持，而強大的雲端分析基礎設施也為之奠定了基礎。這種環境正在推動人工智慧驅動工具的快速商業化，但也面臨著許多挑戰，例如監管力度加大以及對資料安全和病患知情同意框架日益重視。

成熟的平台公司、專業設備製造商、雲端服務供應商和創新Start-Ups如何透過夥伴關係、檢驗和營運彈性來建立其競爭格局。

人工智慧驅動的基因組學領域的競爭動態由成熟的平台公司、專業儀器製造商、雲端運算服務供應商以及新興Start-Ups共同塑造，這些公司將專業知識與創新演算法方法相結合。成熟的平台公司提供定序、分析和支援服務的整合解決方案，而專業儀器製造商則專注於提高通量、準確性和耗材的成本效益。雲端運算服務供應商支援可擴展的模型訓練和推理，降低了缺乏大規模本地基礎設施的機構的進入門檻。

為高階主管提供切實可行的、循序漸進的策略建議，以確保他們透過資料管治、供應鏈彈性、模組化架構和道德管治，從基因組學中的人工智慧中獲取價值。

產業領導者應採取務實且循序漸進的方式將人工智慧融入基因組學，在創新與營運嚴謹性之間取得平衡。首先，應明確與組織能力和監管限制相符的高影響力應用案例，並優先投資於能夠在這些案例中產生可複製價值的項目。初期工作應著重於建立健全的資料管理、來源追蹤和標註標準，以便利用可靠且文件齊全的資料集訓練模型。

混合研究框架結合了專家訪談、文獻整合、獨立基準測試、情境分析和倫理管治審查，以確保獲得穩健且可操作的見解。

本分析的調查方法結合了定性專家訪談、技術文獻的系統評估以及相關人員訪談檢驗，從而得出全面且平衡的結論。關鍵見解來自於與來自學術界、臨床診斷、設備製造和軟體開發等各領域的專家的結構化對話。除訪談外，對同行評審文章、技術預印本、監管指導文件和公開產品規格的嚴格審查，確保了技術評估基於最新證據。

整合技術可能性和操作挑戰：展示數據品質、互通性和協作檢驗將如何決定基因組人工智慧在現實世界中的影響。

人工智慧正在革新基因組學，它提高了生物學假設的生成、檢驗和實用化的速度和準確性。這項技術能夠實現更精準的農業育種、更快更準確的診斷、更簡化的藥物研發流程以及日益個人化的治療策略。然而，進步並非僅僅源自於更複雜的模型。它同樣取決於資料的品質、定序平台和分析工具之間的互通性，以及能夠適應監管和供應鏈波動的穩健營運實務。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：人工智慧技術在基因體學領域的市場

  • 深度學習
    • 自編碼器
    • 卷積類神經網路
    • 循環神經網路
  • 機器學習
    • 強化學習
    • 監督式學習
    • 無監督學習
  • 自然語言處理
    • 情緒分析
    • 文字探勘

第9章：基因組學領域的人工智慧市場：按服務分類

  • 生物資訊服務
    • 註解
    • 數據分析
    • 解釋
  • 諮詢
    • 實施支持
    • 戰略制定
  • 定序服務
    • EXOME定序
    • 轉錄組序列
    • 全基因組定序
  • 軟體平台
    • 基於雲端的
    • 現場

第10章：人工智慧市場類型—基因組定序

  • 次世代定序
    • Illumina
    • Ion Torrent
    • PacBio
  • 桑格定序
    • 微血管
    • 螢光法

第11章：基因體學領域的人工智慧市場：按應用分類

  • 農業和動物基因組學
    • 作物改良
    • 畜牧養殖
  • 診斷
    • 臨床診斷
    • 研究診斷
  • 藥物發現
    • 先導化合物的鑑定
    • 臨床前試驗
    • 目標檢驗
  • 精準醫療
    • 伴隨診斷
    • 個人化治療
    • 藥物基因體學

第12章：基因組學領域的人工智慧市場：按最終用戶分類

  • 學術研究和調查
    • 研究機構
    • 大學
  • 醫院和診所
    • 診斷檢查室
    • 醫療中心
  • 製藥和生物技術
    • 生技公司
    • 大型製藥企業

第13章：基因體學領域的人工智慧市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：基因組學領域的人工智慧市場：按群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：基因組學領域的人工智慧市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國基因體學領域的人工智慧市場

第17章：中國基因組學領域的人工智慧市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • BenevolentAI Ltd.
  • BGI Genomics Co., Ltd
  • Bio-Rad Laboratories, Inc.
  • Data4Cure Inc.
  • Deep Genomics Inc.
  • DNAnexus Inc.
  • Engine Biosciences Pte. Ltd.
  • Exscientia
  • F. Hoffmann-La Roche Ltd
  • Fabric Genomics Inc.
  • FDNA Inc.
  • Freenome Holdings, Inc.
  • Genomics AI
  • Genoox Ltd.
  • Illumina, Inc.
  • insitro
  • International Business Machines Corporation
  • NanoString Technologies, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • SOPHiA Genetics SA
  • Thermo Fisher Scientific Inc.
Product Code: MRR-501246436E27

The Artificial Intelligence in Genomics Market was valued at USD 523.32 million in 2025 and is projected to grow to USD 556.77 million in 2026, with a CAGR of 7.25%, reaching USD 854.43 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 523.32 million
Estimated Year [2026] USD 556.77 million
Forecast Year [2032] USD 854.43 million
CAGR (%) 7.25%

How the convergence of advanced computational models, high-throughput sequencing, and data engineering is redefining discovery, diagnostics, and therapeutic decisions in genomics

Artificial intelligence is rapidly reshaping genomics by combining algorithmic rigor with biological insight to enable discoveries that were previously impractical. Advances in model architectures, increased availability of annotated datasets, and cloud-native compute ecosystems have collectively increased the speed and fidelity with which genomic signals can be interpreted. The convergence of computational methods and high-throughput sequencing has created new modalities for understanding genetic variation, identifying therapeutic targets, and translating molecular signatures into clinically actionable decisions.

Across applications, AI-driven approaches are enhancing capabilities in crop improvement and livestock breeding by enabling more precise trait selection and accelerated breeding cycles, while diagnostics benefit from improved pattern recognition across clinical and research-focused assays to reduce interpretation latency. In drug discovery, computational models are streamlining lead identification, refining target validation, and improving the efficiency of preclinical testing. Within precision medicine, predictive algorithms are informing companion diagnostic development, shaping personalized therapeutic strategies, and supporting pharmacogenomic decision-making.

This introduction frames the remainder of the executive summary by emphasizing the interplay between algorithmic innovation, data fidelity, and service delivery. It underscores that sustained progress will depend on robust annotation and interpretation practices, integration across sequencing platforms, and the alignment of stakeholders in academia, clinical settings, and industry. As a result, leaders must consider both technological opportunity and operational complexity when integrating AI into genomics workflows.

Emerging algorithmic architectures, integrated sequencing-to-analysis workflows, and federated collaboration models that are accelerating translation while raising compliance and validation priorities

The genomic landscape is undergoing transformative shifts driven by deeper model capacity, richer multimodal datasets, and the maturation of end-to-end computational pipelines. Deep learning architectures, including convolutional and recurrent networks, are now routinely applied to tasks that require spatial pattern recognition and temporal sequence interpretation, while autoencoders facilitate dimensionality reduction and latent representation learning that uncover hidden biological relationships. Machine learning paradigms such as supervised and unsupervised learning continue to underpin classification and clustering tasks, and reinforcement learning is beginning to inform experimental design and resource allocation in high-throughput settings. Natural language processing techniques applied to biomedical literature and clinical notes are improving information retrieval and accelerating hypothesis generation.

These methodological shifts are paralleled by service innovation. Bioinformatics services are becoming more modular and cloud-integrated, enabling annotation pipelines and interpretation engines to be consumed as scalable services rather than bespoke projects. Sequencing services are increasingly coupled to analytic platforms so that exome, transcriptome, and whole genome outputs flow directly into validated computational workflows. Consulting practices are transitioning from implementation-only engagements to strategic partnerships that encompass data governance, model validation, and deployment pipelines.

Operationally, the industry is moving toward a more federated model of collaboration where academic institutions, clinical laboratories, and commercial entities share curated datasets through controlled-access mechanisms. This shift reduces duplication of effort, accelerates model training, and enhances reproducibility. At the same time, demand for explainability, provenance tracking, and regulatory compliance is rising, prompting the adoption of standardized ontologies, versioned pipelines, and rigorous validation frameworks. Collectively, these transformative shifts are enabling faster translation of genomic insights into practical applications while raising the bar for quality assurance and ethical stewardship.

Qualitative implications of cumulative U.S. tariff measures on supply chains, procurement strategies, collaborative research practices, and domestic innovation priorities within genomics

U.S. tariff policy dynamics in 2025 have introduced a complex set of qualitative pressures across supply chains, procurement decisions, and research collaborations in genomics. The cumulative effect has been to increase sensitivity to cross-border sourcing, encouraging institutions to revisit vendor selection criteria and to evaluate the resilience of reagent, instrument, and compute supply channels. In practice, this has led many stakeholders to accelerate efforts to diversify suppliers and to explore onshoring or regional manufacturing partnerships for critical consumables and instruments.

From a procurement perspective, higher import levies and administrative friction have incentivized larger organizations to negotiate longer-term contracts to secure price stability, while smaller laboratories and research groups have sought collaborative purchasing consortia or alternative sourcing strategies to mitigate cost volatility. These behaviors are reshaping supplier relationships and shifting commercial conversations toward total cost of ownership, lead time guarantees, and service-level commitments.

Research collaborations and data-sharing arrangements have also adapted. Where cross-border projects previously relied on rapid reagent resupply and instrument service agreements, teams are now placing greater emphasis on data portability and remote analysis capabilities as contingency mechanisms. Cloud-native analysis platforms and software-as-a-service offerings have become essential for maintaining continuity when physical components face tariff-driven delays. At the same time, concerns around intellectual property and data localization have grown, prompting more rigorous contractual frameworks and a renewed focus on local regulatory compliance.

On the innovation front, tariff-induced pressures have spurred domestic investment in alternative technologies, including production of sequencing consumables, modular instrumentation designs that are easier to source locally, and software platforms that reduce reliance on proprietary hardware. While these shifts do not eliminate the tradeoffs associated with specialization and economies of scale, they are reshaping competitive positioning and encouraging new entrants focused on cost-effective domestic solutions. Ultimately, the cumulative impact of tariffs in 2025 has been to accelerate strategic reassessment of supply chains, strengthen the value of integrated analytic services, and increase the importance of operational resilience in genomics workflows.

Segmentation-driven insight into how application needs, algorithmic approaches, service models, sequencing modalities, and end-user priorities determine adoption pathways in genomic AI

A granular segmentation lens reveals where AI in genomics is generating the most actionable value across distinct clinical, agricultural, and commercial contexts. In application domains, agriculture and animal genomics benefit from algorithmic trait selection and genomic selection methods that accelerate crop improvement and livestock breeding, enabling breeders to prioritize yield, resilience, and disease resistance more effectively. Diagnostics encompasses both clinical diagnostic labs and research diagnostics teams; AI complements high-throughput assays by improving variant interpretation and reducing turnaround, while research diagnostics leverage pattern discovery to generate hypotheses for downstream validation. In drug discovery, computational approaches span lead identification, target validation, and preclinical testing, with AI models enhancing virtual screening, predicting off-target effects, and optimizing experimental prioritization. Precision medicine integrates companion diagnostics, personalized therapeutics, and pharmacogenomics to tailor treatments based on predictive biomarkers identified through combined genomic and clinical data.

Regarding AI techniques, advances in deep learning-encompassing autoencoders, convolutional neural networks, and recurrent neural networks-are particularly impactful for sequence-based pattern recognition and representation learning. Machine learning subfields such as supervised, unsupervised, and reinforcement learning remain core to classification, clustering, and optimized experimental strategies. Natural language processing techniques, applied to literature mining and clinical text, facilitate rapid curation of evidence and support translational research by extracting actionable insights from unstructured sources.

Service-oriented segmentation underscores the importance of integrated offerings. Bioinformatics services that deliver annotation, data analysis, and interpretation are foundational for transforming raw sequences into interpretable results. Consulting engagements that address implementation support and strategy development help organizations align technical deployments with clinical and commercial objectives. Sequencing services-spanning exome sequencing, transcriptome sequencing, and whole genome sequencing-feed downstream analytics, while software and platform choices, whether cloud-based or on-premise, determine scalability, data governance, and latency profiles.

Sequencing modality distinctions matter for both analytic pipelines and procurement. Next generation sequencing platforms such as Illumina, Ion Torrent, and PacBio deliver varied read lengths, throughput, and error profiles that influence model training and interpretation strategies. Sanger sequencing, with capillary and fluorescence modalities, continues to serve as a validation and targeted analysis approach. End-user segmentation further differentiates adoption patterns: academic and research institutions, including research institutes and universities, prioritize methodological openness and reproducibility; hospitals and clinics, including diagnostic laboratories and medical centers, emphasize regulatory compliance, turnaround time, and integration with clinical workflows; and pharma and biotech organizations, both biotech firms and large pharmaceutical companies, require scalable pipelines, IP protection, and regulatory-grade validation to support drug development and companion diagnostic strategies.

Taken together, these segmentation insights illustrate that successful AI adoption in genomics requires a nuanced alignment of technique selection, service model, sequencing modality, and end-user priorities. Solutions tailored to the specific combination of application needs and operational constraints will achieve higher adoption and greater downstream impact.

Regional market dynamics shaping commercialization, regulation, and collaborative research in genomic AI across the Americas, EMEA, and Asia-Pacific landscapes

Geographic dynamics materially influence investment patterns, regulatory environments, and collaborative behaviors across the global genomics ecosystem. The Americas continue to demonstrate a strong integration between industry, academic centers, and clinical systems, with mature venture capital networks supporting translational initiatives and robust infrastructure for cloud-based analytics. This environment favors rapid commercialization of AI-driven tools, although it also faces heightened regulatory scrutiny and increasing emphasis on data security and patient consent frameworks.

Europe, Middle East & Africa presents a diverse regulatory mosaic where harmonization efforts coexist with country-level variability in reimbursement and clinical adoption pathways. Public sector investment in genomics and collaborative consortia is a notable feature, and the region places strong emphasis on data protection, ethical governance, and interoperability standards. These priorities shape vendor strategies, encouraging solutions that prioritize privacy-preserving analytics, transparent provenance, and compliance with local health authority requirements.

Asia-Pacific is characterized by a mix of high-throughput sequencing capacity, strong domestic manufacturing in certain markets, and accelerating public-private partnerships that drive large-scale genomic initiatives. Rapid adoption in clinical genomics and agriculture is supported by governments seeking to leverage genomics for national health and food security goals. The region also demonstrates a growing ecosystem of AI talent and cloud infrastructure providers, which together enable localized innovation, faster iteration cycles, and competitive alternatives to incumbent suppliers.

Across these regions, cross-border collaborations persist but are increasingly mediated by considerations of data sovereignty, supply chain resilience, and regulatory alignment. Regional strategies that account for local procurement practices, clinical validation requirements, and cultural expectations around data use will have a distinct advantage in both market penetration and sustained impact.

How platform incumbents, specialized instrument makers, cloud providers, and innovative startups are structuring the competitive landscape through partnerships, validation, and operational resilience

Competitive dynamics in AI-enabled genomics are defined by a mix of platform incumbents, specialized instrument makers, cloud and compute providers, and emerging startups that combine domain expertise with novel algorithmic approaches. Platform incumbents bring integrated solutions that bundle sequencing, analytics, and support services, while specialized instrument manufacturers focus on improvements in throughput, accuracy, and consumable economics. Cloud and compute providers enable scalable model training and inference, lowering barriers for organizations without extensive on-premise infrastructure.

Startups and specialist vendors are differentiating through novel model architectures, targeted datasets, and service offerings that address specific pain points such as clinical-grade interpretability, low-resource deployment, and edge-enabled analytics for decentralized testing. Partnerships between instrument manufacturers and software providers are increasingly common, reflecting the industry preference for end-to-end validated solutions that reduce integration risk for end users. Academic spinouts and consortium-driven initiatives continue to feed the innovation pipeline, often partnering with commercial entities to move discoveries through validation and regulatory pathways.

Successful companies are those that combine technical excellence with reproducible validation regimes, strong data governance practices, and clear value propositions for distinct end users. Firms that invest in transparent model documentation, rigorous benchmarking against independent datasets, and collaborative trials with clinical or agricultural partners are better positioned to overcome adoption barriers. Equally important are strategic alliances that secure supply chain continuity and regional presence, as these operational factors are increasingly influential in procurement decisions.

Practical and phased strategic recommendations for executives to secure value from AI in genomics through data governance, supply resilience, modular architectures, and ethical stewardship

Industry leaders should adopt a pragmatic, phased approach to integrating AI into genomics that balances innovation with operational rigor. Start by defining high-impact use cases that align with organizational capabilities and regulatory constraints, and then prioritize investments that deliver reproducible value within those use cases. Early efforts should focus on establishing robust data curation, provenance tracking, and annotation standards to ensure that models are trained on reliable, well-documented datasets.

Leaders should also develop a hybrid sourcing strategy that mitigates supply chain risk by combining regional suppliers, long-term contracts for critical consumables, and cloud-based failover options for compute and analytics. Strategic partnerships with academic centers and clinical laboratories can accelerate validation and provide access to diverse datasets, while consulting engagements can bridge capability gaps during implementation.

From a technology perspective, adopt modular architectures that allow teams to swap model components and sequencing inputs without disrupting validated workflows. Emphasize explainability and documentation to facilitate regulatory review and clinician acceptance, and invest in continuous monitoring and post-deployment validation to detect model drift and maintain performance. Finally, embed ethical governance and privacy-preserving techniques into program design to build trust with patients, regulators, and commercial partners. These steps will help organizations capture the benefits of AI while managing the operational and reputational risks inherent in genomics applications.

A mixed-methods research framework combining expert interviews, literature synthesis, independent benchmarking, scenario analysis, and ethical governance review to ensure robust actionable insights

The research methodology underpinning this analysis combined qualitative expert elicitation, systematic evaluation of technical literature, and validation through stakeholder interviews to ensure comprehensive and balanced conclusions. Primary insights were derived from structured conversations with domain experts spanning academia, clinical diagnostics, instrument manufacturing, and software development. These interviews were complemented by a rigorous review of peer-reviewed studies, technical preprints, regulatory guidance documents, and publicly disclosed product specifications to ground technical assessments in current evidence.

Analytic rigor was maintained through cross-validation of algorithmic claims against independent benchmarking datasets and by applying reproducibility checks to reported model architectures and performance metrics. Service and commercialization insights were triangulated using procurement case studies, vendor documentation, and practical implementation reports to capture real-world constraints. The analysis also included scenario-based thinking to explore operational responses to external pressures such as supply chain disruptions and evolving regulatory expectations.

Ethical and privacy considerations were explicitly integrated into the methodology. This involved evaluating data governance frameworks, consent mechanisms, and privacy-preserving computational techniques such as federated learning or secure enclaves. Limitations and areas of uncertainty were documented to help readers assess the contextual applicability of the findings and to identify priorities for additional primary research or pilot engagements.

Synthesis of technological promise and operational imperatives showing how data quality, interoperability, and collaborative validation determine real-world impact in genomic AI

AI is catalyzing a step-change in genomic science by improving the speed and fidelity with which biological hypotheses are generated, validated, and translated. The technology is enabling more precise agricultural breeding, faster and more accurate diagnostics, streamlined drug discovery workflows, and increasingly personalized therapeutic strategies. Progress, however, is not merely a function of model sophistication; it depends equally on data quality, interoperability between sequencing platforms and analytic tools, and resilient operational practices that accommodate regulatory and supply chain variability.

Looking ahead, organizations that combine technical rigor with pragmatic operational strategies-strong data stewardship, modular technical architectures, regional supply diversification, and transparent validation practices-will be best positioned to realize sustained impact. Collaboration across academia, clinical systems, industry, and policy makers will remain essential to align incentives, accelerate validation cycles, and ensure that ethical and privacy considerations are not sidelined in the pursuit of technological advancement. By attending to both the scientific and operational dimensions of AI integration, stakeholders can translate computational promise into robust, real-world genomic solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Intelligence in Genomics Market, by AI Technique

  • 8.1. Deep Learning
    • 8.1.1. Autoencoders
    • 8.1.2. Convolutional Neural Networks
    • 8.1.3. Recurrent Neural Networks
  • 8.2. Machine Learning
    • 8.2.1. Reinforcement Learning
    • 8.2.2. Supervised Learning
    • 8.2.3. Unsupervised Learning
  • 8.3. Natural Language Processing
    • 8.3.1. Sentiment Analysis
    • 8.3.2. Text Mining

9. Artificial Intelligence in Genomics Market, by Service

  • 9.1. Bioinformatics Services
    • 9.1.1. Annotation
    • 9.1.2. Data Analysis
    • 9.1.3. Interpretation
  • 9.2. Consulting
    • 9.2.1. Implementation Support
    • 9.2.2. Strategy Development
  • 9.3. Sequencing Services
    • 9.3.1. Exome Sequencing
    • 9.3.2. Transcriptome Sequencing
    • 9.3.3. Whole Genome Sequencing
  • 9.4. Software & Platform
    • 9.4.1. Cloud-Based
    • 9.4.2. On-Premise

10. Artificial Intelligence in Genomics Market, by Sequencing Type

  • 10.1. Next Generation Sequencing
    • 10.1.1. Illumina
    • 10.1.2. Ion Torrent
    • 10.1.3. PacBio
  • 10.2. Sanger Sequencing
    • 10.2.1. Capillary
    • 10.2.2. Fluorescence

11. Artificial Intelligence in Genomics Market, by Application

  • 11.1. Agriculture & Animal Genomics
    • 11.1.1. Crop Improvement
    • 11.1.2. Livestock Breeding
  • 11.2. Diagnostics
    • 11.2.1. Clinical Diagnostics
    • 11.2.2. Research Diagnostics
  • 11.3. Drug Discovery
    • 11.3.1. Lead Identification
    • 11.3.2. Preclinical Testing
    • 11.3.3. Target Validation
  • 11.4. Precision Medicine
    • 11.4.1. Companion Diagnostics
    • 11.4.2. Personalized Therapeutics
    • 11.4.3. Pharmacogenomics

12. Artificial Intelligence in Genomics Market, by End User

  • 12.1. Academic & Research
    • 12.1.1. Research Institutes
    • 12.1.2. Universities
  • 12.2. Hospitals & Clinics
    • 12.2.1. Diagnostic Laboratories
    • 12.2.2. Medical Centers
  • 12.3. Pharma & Biotech
    • 12.3.1. Biotech Firms
    • 12.3.2. Large Pharma

13. Artificial Intelligence in Genomics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Artificial Intelligence in Genomics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Artificial Intelligence in Genomics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Artificial Intelligence in Genomics Market

17. China Artificial Intelligence in Genomics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agilent Technologies, Inc.
  • 18.6. BenevolentAI Ltd.
  • 18.7. BGI Genomics Co., Ltd
  • 18.8. Bio-Rad Laboratories, Inc.
  • 18.9. Data4Cure Inc.
  • 18.10. Deep Genomics Inc.
  • 18.11. DNAnexus Inc.
  • 18.12. Engine Biosciences Pte. Ltd.
  • 18.13. Exscientia
  • 18.14. F. Hoffmann-La Roche Ltd
  • 18.15. Fabric Genomics Inc.
  • 18.16. FDNA Inc.
  • 18.17. Freenome Holdings, Inc.
  • 18.18. Genomics AI
  • 18.19. Genoox Ltd.
  • 18.20. Illumina, Inc.
  • 18.21. insitro
  • 18.22. International Business Machines Corporation
  • 18.23. NanoString Technologies, Inc.
  • 18.24. PerkinElmer, Inc.
  • 18.25. QIAGEN N.V.
  • 18.26. SOPHiA Genetics SA
  • 18.27. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AI TECHNIQUE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SERVICE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AI TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DEEP LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DEEP LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DEEP LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AUTOENCODERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AUTOENCODERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AUTOENCODERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY RECURRENT NEURAL NETWORKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY RECURRENT NEURAL NETWORKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY RECURRENT NEURAL NETWORKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MACHINE LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MACHINE LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY REINFORCEMENT LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY REINFORCEMENT LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY REINFORCEMENT LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SUPERVISED LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SUPERVISED LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SUPERVISED LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY UNSUPERVISED LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY UNSUPERVISED LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY UNSUPERVISED LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SENTIMENT ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SENTIMENT ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SENTIMENT ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY TEXT MINING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY TEXT MINING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY TEXT MINING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SERVICE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ANNOTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ANNOTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ANNOTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY INTERPRETATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY INTERPRETATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY INTERPRETATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONSULTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONSULTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONSULTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONSULTING, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY IMPLEMENTATION SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY IMPLEMENTATION SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY IMPLEMENTATION SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY STRATEGY DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY STRATEGY DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY STRATEGY DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SOFTWARE & PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SOFTWARE & PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SOFTWARE & PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SOFTWARE & PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CLOUD-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CLOUD-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CLOUD-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ON-PREMISE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ON-PREMISE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ON-PREMISE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ILLUMINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ILLUMINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ILLUMINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ION TORRENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ION TORRENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ION TORRENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PACBIO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PACBIO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PACBIO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SANGER SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CAPILLARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CAPILLARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CAPILLARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY FLUORESCENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY FLUORESCENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY FLUORESCENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AGRICULTURE & ANIMAL GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AGRICULTURE & ANIMAL GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AGRICULTURE & ANIMAL GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AGRICULTURE & ANIMAL GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CROP IMPROVEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CROP IMPROVEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CROP IMPROVEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY LIVESTOCK BREEDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY LIVESTOCK BREEDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY LIVESTOCK BREEDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY RESEARCH DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY RESEARCH DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY RESEARCH DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY LEAD IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY LEAD IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY LEAD IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECLINICAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECLINICAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY TARGET VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY TARGET VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECISION MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECISION MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECISION MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECISION MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PERSONALIZED THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PERSONALIZED THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PERSONALIZED THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MEDICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MEDICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MEDICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMA & BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMA & BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMA & BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOTECH FIRMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOTECH FIRMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOTECH FIRMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AI TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SERVICE, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONSULTING, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SOFTWARE & PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SANGER SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AGRICULTURE & ANIMAL GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECISION MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 209. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 210. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AI TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SERVICE, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONSULTING, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SOFTWARE & PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SANGER SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AGRICULTURE & ANIMAL GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECISION MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AI TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SERVICE, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONSULTING, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SOFTWARE & PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SANGER SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AGRICULTURE & ANIMAL GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECISION MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AI TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SERVICE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONSULTING, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SOFTWARE & PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SANGER SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AGRICULTURE & ANIMAL GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRIC